Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Reuters raises all components of PTSC's rating to Outperform

Reuters raises all components of PTSC's rating to Outperform

posted on Feb 21, 2008 10:57AM

Although Reuters has been giving PTSC its highest overall rating of Outperform for some time now, one component making up the overall composite was rated Neutral. That component, "Technical Factors", was very recently raised from Neutral to Outperform. Now all four components of the composite score are rated Outperform.

Fundamental Quality Component: Outperform

This rating is based on characteristics traditionally associated with "good" companies. We focus on how each company measures up against others, and give careful attention to recent improvement or slippage relative to other companies.

Value Catch-up Component: Outperform

This rating measures the extent to which the share price adequately reflects improving or eroding fundamentals, and favors shares whose prices have been slower to "catch up" to improving performance measures.

Operational Trends Component: Outperform

This rating reflects how strong a company's recent Sales and EPS (reported as per GAAP) growth have been relative to other companies we rate.

Technical Factors: Outperform

This rating is based on analyses of share price movements over a variety of time periods. We compare performance characteristics of individual stocks with those of all the others we rate. Generally speaking, our goal is to favor up-trending shares that have experienced recent corrections and de-emphasize down-trending shares experiencing uncharacteristic periods of strength. Here is how PTSC shares performed during the various periods we examined.

Share
New Message
Please login to post a reply